Cover Image
市場調查報告書

發炎性疼痛 - 開發平台分析

Inflammatory Pain - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251546
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
發炎性疼痛 - 開發平台分析 Inflammatory Pain - Pipeline Review, H2 2014
出版日期: 2014年07月31日 內容資訊: 英文 164 Pages
簡介

特徵為伴隨發炎的疼痛。由於受傷或發炎促進分泌大量炎症介體。症狀有電擊般的疼痛、持續疼痛、頻發性疼痛等。外部壓力及環境要素很容易造成症狀的惡化。發炎性疼痛可藉由止痛藥等藥劑加以控制。

本報告提供發炎性痛覺的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊,以及最新的新聞和發表。

簡介

  • 調查範圍

發炎性疼痛 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • Kyowa Hakko Kirin
  • 鹽野義製藥
  • AstraZeneca PLC
  • MedImmune, LLC
  • Merck & Co., Inc.
  • 武田藥品工業
  • Glenmark Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Evotec AG
  • Anavex Life Sciences Corp.
  • Array BioPharma Inc.
  • Pluristem Therapeutics Inc.
  • BCN Peptides, S.A.
  • Upsher-Smith Laboratories, Inc.
  • Grunenthal GmbH
  • Integral Molecular, Inc.
  • AngioChem Inc.
  • 旭化成製藥
  • Hydra Biosciences, Inc.
  • NeurAxon, Inc.
  • Cara Therapeutics, Inc.
  • CLL Pharma
  • Dompe Farmaceutici S.p.A.
  • Lohocla Research Corporation
  • MAKScientific, LLC
  • RaQualia Pharma Inc.
  • Sunovion Pharmaceuticals Inc.
  • Adynxx, Inc.
  • Kareus Therapeutics, SA
  • AnaBios Corporation
  • Creabilis SA
  • Istituto Italiano di Tecnologia
  • Infirst Healthcare Limited
  • AbbVie Inc.
  • Epirus Biopharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • grapiprant
  • Z-944
  • DD-04107
  • S-120083
  • SYN-1002
  • GBR-900
  • Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence
  • Small Molecule to Antagonize Bradykinin Receptor B1 for Pain
  • OX-MPI
  • Small Molecule to Inhibit nNOS/iNOS for Inflammatory Pain
  • HC-030031
  • CR-845
  • Small Molecule to Antagonize TrkA for Inflammatory Pain
  • ANAVEX-1079
  • ANG-2002
  • AMAP-102
  • CT-340
  • RQ-00000008
  • CR-701
  • Small molecules To Inhibit CDK9 for Central Nervous System and Immunology
  • AK-106
  • Z-212
  • Stem Cell Therapy for Neuropathic and Inflammatory Pain
  • conolidine
  • AYX-3
  • Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis
  • Biologic 2 for Central Nervous System
  • Drugs to Inhibit SRC-ND2 Interaction for Neuropathic Pain and Inflammatory Pain
  • Small Molecule Targeting Cannabinoid Receptor For Inflammatory Pain
  • AR-786
  • AZ-1
  • AZ-2
  • Small Molecule to Inhibit FAAH for Pain
  • Small Molecule for Neuropathic Pain and Inflammatory Pain
  • ZJ-43
  • Drug to Inhibit Glutaminase for Inflammatory Pain
  • MK-8825
  • MAK-2124
  • A-836339
  • Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment
  • ibuprofen
  • Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders
  • PNU-120596
  • AB-144
  • NET-END
  • PF-3845
  • BIBN-4096BS
  • Peptide to Block Calcium Channel for CNS Disorders
  • Small Molecules to Inhibit TRPA1 and TRPV1 for CNS
  • URB-937
  • BBI-11008
  • A-1048400
  • NH-34
  • K-685
  • ET-1
  • GRTTA-2210
  • RO-656570
  • FV-082
  • FV-137
  • Small Molecules to Antagonize Cav3.2 for Pain
  • DF-2593A
  • UNC-3230
  • Kindolor
  • Nav 1.7 Blocker Program
  • Nav1.8 Sodium Channel Blocker For Pain
  • Biologic 1 for Central Nervous System
  • Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain

最近的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5198IDB

Summary

Global Markets Direct's, 'Inflammatory Pain - Pipeline Review, H2 2014', provides an overview of the Inflammatory Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammatory Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Inflammatory Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Inflammatory Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Inflammatory Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Inflammatory Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Inflammatory Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Inflammatory Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Inflammatory Pain Overview
  • Therapeutics Development
    • Pipeline Products for Inflammatory Pain - Overview
    • Pipeline Products for Inflammatory Pain - Comparative Analysis
  • Inflammatory Pain - Therapeutics under Development by Companies
  • Inflammatory Pain - Therapeutics under Investigation by Universities/Institutes
  • Inflammatory Pain - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Inflammatory Pain - Products under Development by Companies
  • Inflammatory Pain - Products under Investigation by Universities/Institutes
  • Inflammatory Pain - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim GmbH
    • Kyowa Hakko Kirin Co., Ltd.
    • Shionogi & Co., Ltd.
    • AstraZeneca PLC
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Takeda Pharmaceutical Company Limited
    • Glenmark Pharmaceuticals Ltd.
    • Pfizer Inc.
    • Evotec AG
    • Anavex Life Sciences Corp.
    • Array BioPharma Inc.
    • Pluristem Therapeutics Inc.
    • BCN Peptides, S.A.
    • Upsher-Smith Laboratories, Inc.
    • Grunenthal GmbH
    • Integral Molecular, Inc.
    • AngioChem Inc.
    • Asahi Kasei Pharma Corp.
    • Hydra Biosciences, Inc.
    • NeurAxon, Inc.
    • Cara Therapeutics, Inc.
    • CLL Pharma
    • Dompe Farmaceutici S.p.A.
    • Lohocla Research Corporation
    • MAKScientific, LLC
    • RaQualia Pharma Inc.
    • Sunovion Pharmaceuticals Inc.
    • Adynxx, Inc.
    • Kareus Therapeutics, SA
    • AnaBios Corporation
    • Creabilis SA
    • Istituto Italiano di Tecnologia
    • Infirst Healthcare Limited
    • AbbVie Inc.
    • Epirus Biopharmaceuticals, Inc.
  • Inflammatory Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • grapiprant - Drug Profile
    • Z-944 - Drug Profile
    • DD-04107 - Drug Profile
    • S-120083 - Drug Profile
    • SYN-1002 - Drug Profile
    • GBR-900 - Drug Profile
    • Small Molecule to Antagonize P2X3 and P2X2/3 for Inflammatory Pain, Neuropathic Pain and Urinary Incontinence - Drug Profile
    • Small Molecule to Antagonize Bradykinin Receptor B1 for Pain - Drug Profile
    • OX-MPI - Drug Profile
    • Small Molecule to Inhibit nNOS/iNOS for Inflammatory Pain - Drug Profile
    • HC-030031 - Drug Profile
    • CR-845 - Drug Profile
    • Small Molecule to Antagonize TrkA for Inflammatory Pain - Drug Profile
    • ANAVEX-1079 - Drug Profile
    • ANG-2002 - Drug Profile
    • AMAP-102 - Drug Profile
    • CT-340 - Drug Profile
    • RQ-00000008 - Drug Profile
    • CR-701 - Drug Profile
    • Small molecules To Inhibit CDK9 for Central Nervous System and Immunology - Drug Profile
    • AK-106 - Drug Profile
    • Z-212 - Drug Profile
    • Stem Cell Therapy for Neuropathic and Inflammatory Pain - Drug Profile
    • conolidine - Drug Profile
    • AYX-3 - Drug Profile
    • Small Molecule to Antagonize 5-HT2 Receptor for Cardiovascular, Inflammation, Inflammatory Pain and Fibrosis - Drug Profile
    • Biologic 2 for Central Nervous System - Drug Profile
    • Drugs to Inhibit SRC-ND2 Interaction for Neuropathic Pain and Inflammatory Pain - Drug Profile
    • Small Molecule Targeting Cannabinoid Receptor For Inflammatory Pain - Drug Profile
    • AR-786 - Drug Profile
    • AZ-1 - Drug Profile
    • AZ-2 - Drug Profile
    • Small Molecule to Inhibit FAAH for Pain - Drug Profile
    • Small Molecule for Neuropathic Pain and Inflammatory Pain - Drug Profile
    • ZJ-43 - Drug Profile
    • Drug to Inhibit Glutaminase for Inflammatory Pain - Drug Profile
    • MK-8825 - Drug Profile
    • MAK-2124 - Drug Profile
    • A-836339 - Drug Profile
    • Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment - Drug Profile
    • ibuprofen - Drug Profile
    • Small Molecule to Antagonize P2X3 Receptor for Central Nervous System Disorders - Drug Profile
    • PNU-120596 - Drug Profile
    • AB-144 - Drug Profile
    • NET-END - Drug Profile
    • PF-3845 - Drug Profile
    • BIBN-4096BS - Drug Profile
    • Peptide to Block Calcium Channel for CNS Disorders - Drug Profile
    • Small Molecules to Inhibit TRPA1 and TRPV1 for CNS - Drug Profile
    • URB-937 - Drug Profile
    • BBI-11008 - Drug Profile
    • A-1048400 - Drug Profile
    • NH-34 - Drug Profile
    • K-685 - Drug Profile
    • ET-1 - Drug Profile
    • GRTTA-2210 - Drug Profile
    • RO-656570 - Drug Profile
    • FV-082 - Drug Profile
    • FV-137 - Drug Profile
    • Small Molecules to Antagonize Cav3.2 for Pain - Drug Profile
    • DF-2593A - Drug Profile
    • UNC-3230 - Drug Profile
    • Kindolor - Drug Profile
    • Nav 1.7 Blocker Program - Drug Profile
    • Nav1.8 Sodium Channel Blocker For Pain - Drug Profile
    • Biologic 1 for Central Nervous System - Drug Profile
    • Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
  • Inflammatory Pain - Recent Pipeline Updates
  • Inflammatory Pain - Dormant Projects
  • Inflammatory Pain - Discontinued Products
  • Inflammatory Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Inflammatory Pain, H2 2014
  • Number of Products under Development for Inflammatory Pain - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Development by Companies, H2 2014 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Development by Companies, H2 2014 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Inflammatory Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014
  • Inflammatory Pain - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014
  • Inflammatory Pain - Pipeline by Shionogi & Co., Ltd., H2 2014
  • Inflammatory Pain - Pipeline by AstraZeneca PLC, H2 2014
  • Inflammatory Pain - Pipeline by MedImmune, LLC, H2 2014
  • Inflammatory Pain - Pipeline by Merck & Co., Inc., H2 2014
  • Inflammatory Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
  • Inflammatory Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014
  • Inflammatory Pain - Pipeline by Pfizer Inc., H2 2014
  • Inflammatory Pain - Pipeline by Evotec AG, H2 2014
  • Inflammatory Pain - Pipeline by Anavex Life Sciences Corp., H2 2014
  • Inflammatory Pain - Pipeline by Array BioPharma Inc., H2 2014
  • Inflammatory Pain - Pipeline by Pluristem Therapeutics Inc., H2 2014
  • Inflammatory Pain - Pipeline by BCN Peptides, S.A., H2 2014
  • Inflammatory Pain - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014
  • Inflammatory Pain - Pipeline by Grunenthal GmbH, H2 2014
  • Inflammatory Pain - Pipeline by Integral Molecular, Inc., H2 2014
  • Inflammatory Pain - Pipeline by AngioChem Inc., H2 2014
  • Inflammatory Pain - Pipeline by Asahi Kasei Pharma Corp., H2 2014
  • Inflammatory Pain - Pipeline by Hydra Biosciences, Inc., H2 2014
  • Inflammatory Pain - Pipeline by NeurAxon, Inc., H2 2014
  • Inflammatory Pain - Pipeline by Cara Therapeutics, Inc., H2 2014
  • Inflammatory Pain - Pipeline by CLL Pharma, H2 2014
  • Inflammatory Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2014
  • Inflammatory Pain - Pipeline by Lohocla Research Corporation, H2 2014
  • Inflammatory Pain - Pipeline by MAKScientific, LLC, H2 2014
  • Inflammatory Pain - Pipeline by RaQualia Pharma Inc., H2 2014
  • Inflammatory Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014
  • Inflammatory Pain - Pipeline by Adynxx, Inc., H2 2014
  • Inflammatory Pain - Pipeline by Kareus Therapeutics, SA, H2 2014
  • Inflammatory Pain - Pipeline by AnaBios Corporation, H2 2014
  • Inflammatory Pain - Pipeline by Creabilis SA, H2 2014
  • Inflammatory Pain - Pipeline by Istituto Italiano di Tecnologia, H2 2014
  • Inflammatory Pain - Pipeline by Infirst Healthcare Limited, H2 2014
  • Inflammatory Pain - Pipeline by AbbVie Inc., H2 2014
  • Inflammatory Pain - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Inflammatory Pain Therapeutics - Recent Pipeline Updates, H2 2014
  • Inflammatory Pain - Dormant Projects, H2 2014
  • Inflammatory Pain - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Inflammatory Pain, H2 2014
  • Number of Products under Development for Inflammatory Pain - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top